do the DD
@adamfeuerstein $ADXS $INCY collaborating on combo I-O study in cervical cancer is huge for I-O combo data.
FBR Capital analyst Andrew Berens said this trial, "besides paving the way for a combination of Achillion’s NS5b nuc (ACH-3422) plus ACH-3102, shows that the drug could have excellent synergy with Gilead’s Sovaldi." Ultimately the company could be a takeover target for Gilead and AbbVie, as well as Bristol-Myers, Johnson & Johnson, and Roche. "Source: Street Insider"
Biotech to see continued growth in 2015: HC Wainwright
by Mourad Haroutunian
Both Advaxis (NASDAQ:ADXS) has benefited from this strong interest, the research firm said. In Deceber, Marque Investors Adage Capital Management and T. Rowe Price Associates invested nearly $17 million into Advaxis
1/19/2015 JUNO Funding Flowing Freely & In Large Sums
Jan 19, 2015
Juno's whopping $120 million success signals new investing style
Entrepreneurs working to develop new therapies often struggle to find the cash they need to turn their
ideas into million—or billion—dollar companies. But for some, startup funding seems to be flowing freely, and in larger sums than it did in the past Less
Leerink Saying Tonight, JUNO Has at least $30 Upside.. On Monday Quiet period Is over which means the under writers of JUNO will give their targets. The under writers of a stock always give nice targets. Will be a game changer when quiet period over.